| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Voyager Therapeutics (NASDAQ:VYGR) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
Voyager Therapeutics beat estimated earnings by 531.0%, reporting an EPS of $1.25 versus an estimate of $-0.29.
Revenue was up $91.61 million from the same period last year.
Last quarter the company missed on EPS by $0.01 which was followed by a 5.0% increase in the share price the next day.
Here's a look at Voyager Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.58 | -0.59 | 0.77 | -0.55 |
| EPS Actual | -0.59 | -0.51 | 2.94 | -0.61 |
| Revenue Estimate | 2.91M | 2.00M | 41.00M | 4.19M |
| Revenue Actual | 4.61M | 4.85M | 150.48M | -1M |
To track all earnings releases for Voyager Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VYGR
